Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00383123 |
The purpose of this study is to compare two influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Condition | Intervention | Phase |
---|---|---|
Influenza |
Biological: Fluzone Biological: Fluarix |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Subject), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Single-Blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix® (GSK Biologicals) Compared With Fluzone® (Aventis Pasteur/Sanofi) Administered Intramuscularly in Children (6 Months and Older) |
Enrollment: | 3327 |
Study Start Date: | October 2006 |
Study Completion Date: | October 2007 |
Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Fluarix Group: Experimental
Subjects in this group will be further stratified by 3 age groups
|
Biological: Fluarix
Intramuscular injection, one or two doses
|
Fluzone Group: Active Comparator
Subjects in this group will be further stratified by 3 age groups
|
Biological: Fluzone
Intramuscular injection, one or two doses
|
Ages Eligible for Study: | 6 Months to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 104858 |
Study First Received: | September 29, 2006 |
Results First Received: | October 15, 2008 |
Last Updated: | December 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00383123 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Influenza Fluarix |
Virus Diseases Respiratory Tract Diseases Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections |
Virus Diseases RNA Virus Infections Respiratory Tract Diseases |
Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections |